- Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
- Provides Novavax (NASDAQ:) with cash and an equity investment totalling approximately
$1.2 billion (upfront payment of$500 million and up to$700 million in additional development, regulatory and launch milestones), plus tiered royalties - Novavax is entitled to additional launch and sales milestone opportunities of up to
$200 million , plus mid-single digit royalties, for each additional Sanofi (NASDAQ:) vaccine product developed under a non-exclusive license with Novavax’s Matrix-M™ adjuvant technology - Accelerates potential for development of a novel COVID-19-Influenza combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering individuals enhanced convenience and protection
The terms of the agreement include: a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in
“With flu and COVID-19 hospital admission rates now closely mirroring each other, we have an opportunity to develop non-mRNA flu-COVID-19 combination vaccines, offering patients both enhanced convenience and protection against two serious respiratory viruses,” said
Click Here to Read the Full Original Article at All News…